Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Endocrine Maintenance in HR+/HER2- Breast Cancer
NCT05890287Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tucidinostat in Hormone-Receptor-Positive Breast Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started May 2023; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05890287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890287.